Introduction
Factor VIIa occurs naturally in the body and combines with exposed Tissue Factor in the wall of injured blood vessels and possibly on platelets to activate the clotting cascade. Factor VIIa is also involved in the activation of clotting factors on the surface of platelets. [1] Recombinant Factor VIIa (rFVIIa) is a manufactured version of Factor VIIa for intravenous administration. [2] rFVIIa is licensed for treatment of bleeding episodes in patients with haemophilia A or B and patients with deficiencies of certain clotting factors (inhibitors of factors VIII and IX; congenital factor VII deficiency). [3, 4] It is also approved for prevention of bleeding in surgical interventions or invasive procedures in these patients. [5] Use of rFVIIa in trauma is currently an 'off label' use. The aim of this article is to set out current UK guidance on use of rFVIIa in trauma in the deployed military setting.
Haemorrhage management
Uncontrolled bleeding remains a significant cause of death in both civilian [6, 7] and military [8] trauma patient groups. The initial management of bleeding is a combination of simple measures to control external bleeding (pressure, elevation) progressing to the use of tourniquets and/or topical haemostatic agents depending on the site of injury.
Advances in UK military training and equipment since early 2005 have enhanced the capability to aggressively treat catastrophic external haemorrhage. [9] Resuscitation for noncompressible internal haemorrhage includes the use of blood and blood products (fresh thawed plasma, cryoprecipitate and platelets) and early appropriate surgery. In parallel, intensive care measures to prevent or treat hypothermia and acidosis that will aggravate coagulopathy are essential in the critically injured.
The use of rFVIIa as an adjunct to standard methods to control traumatic haemorrhage is no longer unusual in civilian practice in the UK or internationally. [10] In a telephone study of 40 UK intensive care units conducted by the Royal Centre for Defence Medicine in September 2006, 80% of ICUs stated they would use rFVIIa as an adjunct to control life-threatening traumatic haemorrhage. [11] European guidelines published in Aug 06 endorse rFVIIa for use in blunt trauma as an adjunct to control massive bleeding when conventional measures have failed. [12] 
Animal evidence for rFVIIa in trauma
The potential for rFVIIa as an adjunct to traumatic haemorrhage has generated substantial objective large animal research published in open sources (see reference 10 for primary sources). None of the published animal studies to date have demonstrated any evidence of thrombotic complications and several have reported significantly reduced volumes of haemorrhage after use of rFVIIa. Most animal studies did not demonstrate an impact on survival, although two studies did show that the use of rFVIIa was associated with a significant increase in survival. The first study showed that a very high dose of rFVIIa increased survival when assessed approximately 1 hour after injury [13] . Most recently, Sapsford et al have demonstrated that a single dose of rFVIIa (180 mcg/kg) in conjunction with a hypotensive resuscitation strategy does improve survival time over a period of 6 hours in an arterial model of incompressible haemorrhage [14] . This could potentially buy time on the battlefield.
Human evidence for rFVIIa in trauma
rFVIIa is in regular use in the international civilian community as an adjunct to traumatic haemorrhage management and many rFVIIa should only be considered after:
• Surgical control and/or embolisation (note: embolisation not available in a deployed setting).
• Use of blood products.
• Correction of factors that inhibit coagulation (hypothermia, severe acidosis, low haemotocrit, hypocalcaemia). rFVIIa is not a substitute for these phases of resuscitation.
CLINICAL DEVELOPMENTS
institutions have implemented guidelines for its use in these circumstances. [15] Kenet et al described the first use in a trauma patient (an Israeli soldier) in 1999. [16] There are multiple additional anecdotal reports and some limited case series. [17, 18] Boffard et al have published the only RCT in relation to the use of rFVIIa in trauma, which found that rFVIIa significantly reduced the need for red blood cell transfusion and massive blood transfusions in blunt trauma patients and that there was a trend toward reduction in penetrating trauma. [19] However, this is not the only RCT for rFVIIa controlling haemorrhage in humans: Freiderich et al reported success in radical prostate surgery, showing a decrease in blood loss and transfusion requirements. [20] A five year retrospective cohort study at a Canadian Level 1 trauma centre has concluded that rFVIIa may improve early survival of massively bleeding trauma patients, although surgical control of haemorrhage remains the principal therapeutic aim. [21] The joint Australian and New Zealand Haemostasis Registry has 695 cases where rFVIIa has been used, 108 for trauma from 19 hospitals (87% blunt, 10% penetrating, 83% ISS>16) [22] . This represents a large series of rFVIIa use in trauma outside a randomized controlled trial. rFVIIa was found to be effective in controlling haemorrhage in 59% of cases. Analysis of the dataset has shown rFVIIa to be less effective in severe acidosis (pH<7.05) and/or hypothermia (T<35º C) with the best predictors of success in a multivariate analysis being pH, temperature and ISS.
US military experience of rFVIIa has been extensive and includes multiple military personnel injured by Improvised Explosive Device (IED) attacks [23] . The injury mechanism of IED attack is a combination of blunt, blast, burn and penetrating injury. rFVIIa use in UK military operational casualties to date has been limited, with less than 20 recorded uses on the Joint Theatre Trauma Registry. One of these is the subject of a published report [24] . A detailed analysis of usage will be published independently.
Dosage
Based on the trial by Boffard et al, the European guidelines are for an initial dose of 200mcg/kg followed by two doses of 100mcg /kg at 1 and 3 hours after the first dose. This is higher than the doses recommended on the product data sheet for use in Haemophilia A or B patients with inhibitors (for bleeding episodes use 90mcg/kg every 2 hours until haemostasis is achieved; for surgical intervention use 90mcg/kg before the intervention and repeated at 2 hourly intervals for the duration of surgery) and higher than the those for congenital Factor VII deficiency (15-30mcg/kg every 4-6 hours until haemostasis achieved).
The dose in use at the US 10th Combat Support Hospital in Baghdad in 2006 was~100mcg/kg initially, repeated at 1 hour if clinically indicated.
Complications
rFVIIa is a potent pro-coagulant with the potential for thromboembolic adverse events in susceptible patients.
An analysis of safety of 400,000 standard doses of rFVIIa in haemophiliacs showed <1% incidence of serious adverse effects and <0.05% serious thrombotic events (not dose-related). [25] In a study of 285 patients who received rFVIIa for traumatic haemorrhage at R. Adams Cowley Shock Trauma Center in Baltimore (2001-2006) looking specifically into complications of rFVIIa, 9.4% of patients had developed thromboembolic complications of which 3.1% were thought to be highly probably related to rFVIIa. [26] This is highly consistent with other large scale rFVIIa studies. [27] The Australian and New Zealand registry data recorded no adverse events which were "definitely" or "probably" causally related to rFVIIa use, but 3 cases where it was "possibly" implicated. Thromboembolic complications occurred in 3% patients, which is similar to that reported in other trauma series without rFVIIa use.
It is recognised that there may be morbidity from use of rFVIIa. However, as this drug is only advocated for lifethreatening haemorrhage that cannot be controlled by conventional means, the ethical balance is in favour of administering the drug in these circumstances.
Current recommendations
Current UK military recommendations are summarized in Table 2 :
The dose of 100mcg/kg utilised by US military is recommended when criteria are met for rFVIIa as an adjunct to massive traumatic haemorrhage.
Summary
UK DMS policy for haemorrhage management is under regular review and the use of haemostatic agents and injected rFVIIa will continue to be assessed as further evidence emerges from US, European and Israeli experience, both civilian and military. Published US military experience of aggressive use of fresh frozen plasma in tandem with packed cells has now been implemented as part of the UK DMS evolving strategy to manage massive transfusion needs within the emerging concept of damage control resuscitation [28] . -Blood loss at a rate of 1.5 ml kg -1 min -1 for 20 minutes or more • In practical terms, rFVIIa should be considered if there is evidence of continued bleeding after 6-8 units of packed red blood cells and correction of coagulopathy with fresh frozen plasma.
• rFVIIa 100mcg/kg IV bolus (with a 2nd bolus after 20mins if required) may be advocated as an adjunct in controlling haemorrhage following blunt trauma.
• Consultant clinician discretion must determine if there is a blunt component to blast injury that may respond to rFVIIa when conventional measures have failed.
• European guidelines recommend informing the patient or next of kin before using rFVIIa in an 'off label' manner: this is impractical in the context of managing severe military trauma casualties overseas.
• Contraindications to rFVIIa use as an adjunct to traumatic haemorrhage are: -Patient is expected to be unsalvegeable despite rFVIIa -Known or suspected ischaemic heart disease -History of thrombo-embolic event in the preceding 6 months
